B+
Bull case
0%
Probability
Target price
$205.00
+19.2% vs current
NBIX
Neurocrine BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$188.00
+9.3% vs current
B-
Bear case
0%
Probability
Target price
$154.00
-10.5% vs current
AI sentiment snapshot
Latest data as of 2026-07-03
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+53.3
Score
AI commentary
As of July 3, 2026, the evidence base is still primary-source strong because the May 5, 2026 earnings 8-K, May 5, 2026 10-Q, and May 14, 2026 8-K clearly support the commercial trajectory and confirm the Soleno close. But this packet lacks a usable post-close analyst-revision set, has no meaningful social coverage, and offers limited fresh trusted-news context, so the stance remains constructive but monitoring-oriented rather than aggressively bullish.
RankAlpha Sentiment Codex - 2026-07-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-18eventSoleno close is complete, shifting focus to integration and VYKAT XR contributionMedium impact
Neurocrine completed the Soleno acquisition on May 18, 2026 after 88.9% of Soleno shares were tendered, making Soleno a wholly owned subsidiary. That removes deal-close risk, but investors now need evidence that VYKAT XR integration and rare-disease portfolio expansion support the revenue-growth case implied by the transaction. [#SEC-10Q-2026-05-05]
2026-07-30catalystQ1 commercial momentum and INGREZZA guidance need to hold into the next operating checkMedium impact
First-quarter 2026 net product sales were $811.0 million, including INGREZZA net product sales of $656.9 million and CRENESSITY net product sales of $153.3 million, while Neurocrine reaffirmed 2026 full-year INGREZZA net sales guidance of $2.7 billion to $2.8 billion. The key near-term question is whether prescription growth and CRENESSITY reimbursement durability continue to offset lower INGREZZA net price. [#SEC-8K-2026-05-05]
2026-12-31catalystPipeline breadth improved, but rerating still needs later data rather than study starts aloneHigh impact
Neurocrine said it initiated and dosed the first patients in a Phase 2 study of NBI-1117570 in adults with schizophrenia and initiated a Phase 1 first-in-human study for NBIP-2118 in obesity. Those starts support platform breadth, but valuation upside still depends on later efficacy and development execution rather than simple multiple expansion from early-stage progress. [#SEC-8K-2026-05-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-03 • Updated nightlySource: Internal modelMethodology